Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges
- PMID: 28430610
- PMCID: PMC5464922
- DOI: 10.18632/oncotarget.15411
Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges
Abstract
Portal vein tumor thrombus is a frequent, challenging complication in hepatocellular carcinoma. Hepatocellular carcinoma patients with portal vein tumor thrombus may show worse liver function, less treatment tolerance and worse prognosis than patients without portal vein tumor thrombus, and they may be at higher risk of comorbidity related to portal hypertension. Western and some Asian guidelines stratify hepatocellular carcinoma with portal vein tumor thrombus together with metastatic hepatocellular carcinoma and therefore recommend only palliative treatment with sorafenib or other systemic agents. In recent years, more treatment options have become available for hepatocellular carcinoma patients with portal vein tumor thrombus, and an evidence-based approach to optimizing disease management and treatment has become more widespread. Nevertheless, consensus policies for managing hepatocellular carcinoma with portal vein tumor thrombus have not been established. This comprehensive literature review, drawing primarily on studies published after 2010, examines currently available management options for patients with hepatocellular carcinoma and portal vein tumor thrombus.
Keywords: hepatic resection; hepatocellular carcinoma; portal vein tumor thrombosis; transarterial chemoembolization.
Conflict of interest statement
There is no conflict of interest.
Similar articles
-
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.World J Gastroenterol. 2016 Apr 7;22(13):3632-43. doi: 10.3748/wjg.v22.i13.3632. World J Gastroenterol. 2016. PMID: 27053855 Free PMC article.
-
Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition.Oncotarget. 2017 Jan 31;8(5):8867-8876. doi: 10.18632/oncotarget.12817. Oncotarget. 2017. PMID: 27780939 Free PMC article. Review.
-
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.World J Gastroenterol. 2017 Nov 21;23(43):7735-7745. doi: 10.3748/wjg.v23.i43.7735. World J Gastroenterol. 2017. PMID: 29209114 Free PMC article. Clinical Trial.
-
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246. World J Gastroenterol. 2015. PMID: 25574098 Free PMC article.
-
Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.J Gastrointest Cancer. 2025 Jul 23;56(1):162. doi: 10.1007/s12029-025-01280-2. J Gastrointest Cancer. 2025. PMID: 40699271 Free PMC article. Review.
Cited by
-
A Machine Learning Model Based on Counterfactual Theory for Treatment Decision of Hepatocellular Carcinoma Patients.J Hepatocell Carcinoma. 2024 Aug 30;11:1675-1687. doi: 10.2147/JHC.S470550. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39229347 Free PMC article.
-
Characterizing PTP4A3/PRL-3 as the Potential Prognostic Marker Gene for Liver Hepatocellular Carcinoma.J Oncol. 2022 Sep 30;2022:2717056. doi: 10.1155/2022/2717056. eCollection 2022. J Oncol. 2022. PMID: 36213837 Free PMC article.
-
Construction of HBV gene-related prognostic and diagnostic models for hepatocellular carcinoma.Front Genet. 2023 Jan 4;13:1065644. doi: 10.3389/fgene.2022.1065644. eCollection 2022. Front Genet. 2023. PMID: 36685852 Free PMC article.
-
Development and Validation of CAGIB Score for Evaluating the Prognosis of Cirrhosis with Acute Gastrointestinal Bleeding: A Retrospective Multicenter Study.Adv Ther. 2019 Nov;36(11):3211-3220. doi: 10.1007/s12325-019-01083-5. Epub 2019 Sep 11. Adv Ther. 2019. PMID: 31512140 Free PMC article.
-
Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway.J Exp Clin Cancer Res. 2018 Jun 28;37(1):128. doi: 10.1186/s13046-018-0787-2. J Exp Clin Cancer Res. 2018. PMID: 29954442 Free PMC article.
References
-
- Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016(66):115–132. - PubMed
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016(66):7–30. - PubMed
-
- Yuan BH, Yuan WP, Li RH, Xiang BD, Gong WF, Li LQ, Zhong JH. Propensity score-based comparison of hepatic resection and transarterial chemoembolization for patients with advanced hepatocellular carcinoma. Tumour Biol. 2016(37):2435–2441. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical